Retrospective observational study Among Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Anaplastic Lymphoma Kinase (ALK) Inhibitors
Latest Information Update: 04 Jun 2021
At a glance
- Drugs Alectinib (Primary) ; Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jun 2021 New trial record
- 20 May 2021 Results presented at the 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research